The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus

Mi Seon Shin, Ji Hee Yu, Chang Hee Jung, Jenie Yoonoo Hwang, Woo Je Lee, Min Seon Kim, Joong Yeol Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.

Original languageEnglish
Pages (from-to)1033-1042
Number of pages10
JournalDiabetes Technology and Therapeutics
Volume14
Issue number11
DOIs
Publication statusPublished - 2012 Nov 1
Externally publishedYes

Fingerprint

C-Peptide
Type 2 Diabetes Mellitus
Therapeutics
Fasting
Serum
Hemoglobins
Cohort Studies
Insulin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this

The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus. / Shin, Mi Seon; Yu, Ji Hee; Jung, Chang Hee; Hwang, Jenie Yoonoo; Lee, Woo Je; Kim, Min Seon; Park, Joong Yeol.

In: Diabetes Technology and Therapeutics, Vol. 14, No. 11, 01.11.2012, p. 1033-1042.

Research output: Contribution to journalArticle

Shin, Mi Seon ; Yu, Ji Hee ; Jung, Chang Hee ; Hwang, Jenie Yoonoo ; Lee, Woo Je ; Kim, Min Seon ; Park, Joong Yeol. / The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus. In: Diabetes Technology and Therapeutics. 2012 ; Vol. 14, No. 11. pp. 1033-1042.
@article{5d4938bf76d04a9fa7ec5af6f45bb6fa,
title = "The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus",
abstract = "Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51{\%}) showed decreased C-peptide concentrations, of whom 20{\%} showed a decrease of ≥50{\%}. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4{\%}) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.",
author = "Shin, {Mi Seon} and Yu, {Ji Hee} and Jung, {Chang Hee} and Hwang, {Jenie Yoonoo} and Lee, {Woo Je} and Kim, {Min Seon} and Park, {Joong Yeol}",
year = "2012",
month = "11",
day = "1",
doi = "10.1089/dia.2012.0144",
language = "English",
volume = "14",
pages = "1033--1042",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - The duration of sulfonylurea treatment is associated with β-Cell dysfunction in patients with type 2 diabetes mellitus

AU - Shin, Mi Seon

AU - Yu, Ji Hee

AU - Jung, Chang Hee

AU - Hwang, Jenie Yoonoo

AU - Lee, Woo Je

AU - Kim, Min Seon

AU - Park, Joong Yeol

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.

AB - Background: This study investigated the incidence of β-cell dysfunction and the clinical and biochemical factors affecting that in patients with type 2 diabetes having more than 3 years of follow-up. Subjects and Methods: β-Cell dysfunction was assessed by measuring changes in the fasting serum C-peptide concentrations. Patients were classified into two groups: cases showing a decreased (Group D) or an unchanged or increased (Group I) C-peptide concentration from the baseline. Results: Of the 504 patients included in this study, 259 (51%) showed decreased C-peptide concentrations, of whom 20% showed a decrease of ≥50%. Most patients, however, had a final C-peptide concentration of ≥1ng/mL, with only 18 (4%) individuals having a level <0.6ng/mL. Patients in Group D had a longer duration of diabetes, higher initial hemoglobin A1c concentration, and longer treatment durations with sulfonylurea and insulin compared with Group I. After adjusting for diabetes duration and C-peptide follow-up period, the duration of sulfonylurea treatment was found to be the only factor independently associated with decreases in the C-peptide concentration. Conclusions: Although β-cell function deteriorates over time in patients with type 2 diabetes, these cases mainly have fasting serum C-peptide concentrations of ≥1ng/mL. A longer treatment duration with sulfonylurea is associated with a more rapid decline in the C-peptide concentration.

UR - http://www.scopus.com/inward/record.url?scp=84868020758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868020758&partnerID=8YFLogxK

U2 - 10.1089/dia.2012.0144

DO - 10.1089/dia.2012.0144

M3 - Article

VL - 14

SP - 1033

EP - 1042

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 11

ER -